Clinical Trials
14 trialsNCT04984369 2023-08-21
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
Shanghai Henlius Biotech
Phase 2 Unknown
NCT03284502 2023-08-01
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Unknown
NCT03391934 2023-04-05
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
Phase 3 Unknown
NCT05751512 2023-03-02
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Shanghai Miracogen Inc.
Phase 3 Unknown
NCT05684211 2023-02-01
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.
Phase 2 Unknown
NCT05497336 2022-09-30
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT02675946 2022-01-26
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Curegenix Inc.
Phase 1 Unknown
NCT02826837 2021-10-06
LEAC-102 for Advanced Colorectal Cancer
Taiwan Leader Biotech Corp.
Phase 1/2 Unknown
NCT04466254 2021-08-23
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Unknown
NCT04872634 2021-07-21
SNK_ASTER
NKMAX Co., Ltd.
Phase 1/2 Unknown
NCT03552406 2021-05-06
Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
ISU Abxis Co., Ltd.
Phase 1 Unknown
NCT03491709 2019-10-31
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Dragonboat Biopharmaceutical Company Limited
Phase 1 Unknown
NCT03356158 2018-09-17
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1 Unknown
NCT00931840 2011-09-20
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
Enzon Pharmaceuticals, Inc.
Phase 2 Unknown